Key result
Hollow mesoporous silica nanoparticles used as nanocarriers for FMD VLP vaccines exhibited good biocompatibility, high antibody-response, and protective efficiency comparable to ISA 206.
Why the study?
Foot-and-mouth disease virus-like particle vaccines require delivery systems to elicit a desired immune response.
Hollow mesoporous silica nanoparticles show promise as an effective nanocarrier for foot-and-mouth disease virus-like particle vaccines.
Answers are grounded in this paper and cite their sources.
HMSNs with tailored dimensions support VLP delivery testing; leaves open immunogenicity and protection in relevant models.
Virus-like particle (VLP) vaccine is considered to be the most promising candidate alternative to the traditional inactivated vaccine for foot-and-mouth disease (FMD). To elicit a desired immune response, hollow mesoporous silica nanoparticles (HMSNs) have been synthesized and utilized as a nanocarrier for FMD VLP vaccine delivery. The as-prepared HMSNs displayed a relatively small particle size (∼260 nm), large cavity (∼150 nm), and thin wall (∼55 nm). The inherent structural superiorities make them ideal nanocarriers for the FMD VLP vaccine, which exhibited good biocompatibility, great protein-loading capacity, high antibody-response level, and protective efficiency, even comparable to commercial adjuvant ISA 206. All the results suggested that HMSNs may be a valid nanocarrier in VLP-based vaccines.
No takes yet. Share an insight, caveat, or question.
Ru et al. (2024) studied Foot-and-mouth disease (FMD). Hollow mesoporous silica nanoparticles (HMSNs) as a nanocarrier for FMD VLP vaccine vs. Commercial adjuvant ISA 206 was evaluated on Biocompatibility, protein-loading capacity, antibody-response level, and protective efficiency. Hollow mesoporous silica nanoparticles used as nanocarriers for FMD VLP vaccines exhibited good biocompatibility, high antibody-response, and protective efficiency comparable to ISA 206.
Synapse has enriched 10 related papers. Consider them for comparative context: